3.59
+12.54%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Verrica Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Verrica Pharmaceuticals is based in West Chester, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VRCA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $35.6m and a net loss of $17.9m. At that date it held total assets of $47.1m and shareholders' equity of $24.7m.
We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S. Food and Drug Administration, or FDA, in July 2023 for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are currently developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Our second development candidate, VP-315 (ruxotemitide), is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, or BCC.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 Jun 2018
- Employees
- 76
- Website
- verrica.com ↗
- Head office
- 44 WEST GAY STREET, WEST CHESTER, PA
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Paul ManningChairman of the Board
- Dr. Jayson RiegerPresident, Chief Executive Officer, Director, since 2015$1.2m
- Mr. John KirbyInterim Chief Financial Officer, Interim Principal Financial Officer
- Mr. David ZawitzChief Operating Officer
- Dr. Noah RosenbergChief Medical Officer
- Dr. Gavin CorcoranIndependent Director
- Dr. Lawrence EichenfieldIndependent Director$191,900
- Dr. Diem NguyenIndependent Director$171,900
- Mr. Mark PrygockiIndependent Director$201,900
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 10
- Environment
- 10
- Social
- 12
- Governance
- 9
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates in the specialized medical dermatology sector.
- It has a lead product candidate named VP-102 for skin diseases.
- The firm completed one Phase II clinical trial for its topical solution.
Weaknesses
- The company employs only 29 full-time staff members.
- It is currently in the clinical-stage development phase.
- The business relies on a narrow pipeline of drug-device combinations.
Opportunities
- The firm intends to develop a second candidate VP-103 for plantar warts.
- There is a focus on treating skin diseases with unmet needs.
- Another Phase II trial is being conducted for molluscum treatment.
Threats
- The company faces risks associated with clinical trial outcomes.
- Regulatory hurdles exist for pharmaceutical product commercialization.
- Competition exists within the dermatology and pharmaceutical industries.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.